TY - JOUR
T1 - Adherence to BCR-ABL inhibitors
T2 - Issues for CML therapy
AU - Jabbour, Elias
AU - Saglio, Giuseppe
AU - Radich, Jerald
AU - Kantarjian, Hagop
N1 - Funding Information:
Dr. Jabbour has received honoraria from Bristol-Myers Squibb, Novartis, and Pfizer. Dr. Saglio is a consultant for and has received honoraria from Novartis and Bristol-Myers Squibb. Dr. Radich is a consultant for and has received research grants from Novartis and is a consultant for Bristol-Myers Squibb and Pfizer. Dr. Kantarjian has received research grants from Bristol-Myers Squibb , Pfizer , and Ariad , and is a consultant for and has received research grants from Novartis .
Funding Information:
This report was supported by Bristol-Myers Squibb. The authors acknowledge StemScientific, funded by Bristol-Myers Squibb, for providing writing and editorial support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.
PY - 2012/8
Y1 - 2012/8
N2 - Treatment for chronic myeloid leukemia (CML) has improved substantially in the past 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely receive therapy for the remainder of their lives. In this situation, adherence to medication becomes a concern. Adherence to therapy for chronic health conditions, including CML, has been demonstrated to be poor. Studies have shown nonadherence in CML to be common in one-third or more of patients, and 100% adherence is rare. Furthermore, evidence suggests that reduced adherence to BCR-ABL inhibitors is associated with reduced efficacy and increased healthcare costs. Factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician. To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate.
AB - Treatment for chronic myeloid leukemia (CML) has improved substantially in the past 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely receive therapy for the remainder of their lives. In this situation, adherence to medication becomes a concern. Adherence to therapy for chronic health conditions, including CML, has been demonstrated to be poor. Studies have shown nonadherence in CML to be common in one-third or more of patients, and 100% adherence is rare. Furthermore, evidence suggests that reduced adherence to BCR-ABL inhibitors is associated with reduced efficacy and increased healthcare costs. Factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician. To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate.
KW - Chronic myelogenous leukemia
KW - Dasatinib
KW - Imatinib
KW - Medication possession ratio
KW - Nilotinib
UR - http://www.scopus.com/inward/record.url?scp=84864243295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864243295&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2012.04.002
DO - 10.1016/j.clml.2012.04.002
M3 - Review article
C2 - 22633166
AN - SCOPUS:84864243295
SN - 2152-2650
VL - 12
SP - 223
EP - 229
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 4
ER -